Top Story Today
The FDA Just Rewrote the Playbook for Breast Cancer's Deadliest Subtype
Triple-negative breast cancer just got a new first-line standard of care. The FDA approved Gilead's Trodelvy combined with Merck's Keytruda for PD-L1-positive advanced TNBC, replacing the old Keytruda-plus-chemo regimen after a pivotal trial showed 11.2 months of progression-free survival versus 7.8 months: a 35% reduction in the risk of disease progression or death. The combo pairs an antibody-drug conjugate (a guided missile that delivers chemo directly to cancer cells) with an immune checkpoint inhibitor. For a cancer that lacks the three most common treatment targets, that's a genuinely better hand to play.
Why it matters: This approval accelerates oncology's shift from blunt chemotherapy toward smarter, targeted combinations. For roughly 20% of metastatic TNBC patients who are PD-L1 positive, the treatment landscape meaningfully improved overnight.
Read more →Clinical and Regulatory
The First Muscle-Targeted SMA Drug Just Got Approved
Scholar Rock's Isembyld became the first FDA-approved SMA therapy that targets muscle instead of the underlying genetic defect. In the pivotal SAPPHIRE trial, patients on existing gene-correcting treatments gained a statistically significant 1.8 points in motor function versus placebo. Analysts project $2.2 billion in peak revenue by 2035, and the approval validates a myostatin approach that failed repeatedly in other diseases.
Read more →A Disease So Rare It Had Zero Treatments. Until Now.
Ionis's Zanvastro just became the first-ever approved treatment for Alexander disease, a brain disorder affecting roughly 1 in 2.7 million people. The FDA moved 19 days early on this one. Patients showed a 33.3% improvement in gait speed, and the approval also validates antisense technology in a new category of brain disease: leukodystrophy.
Read more →A One-Shot Gene Therapy Posts Pivotal Win in Blinding Eye Disease
Beacon Therapeutics hit the primary endpoint in its VISTA trial for X-linked retinitis pigmentosa, a disease with zero approved treatments. In the high-dose group, 31% of patients gained at least 15 letters of vision improvement; the untreated control group had zero responders. Regulatory submissions are next for what could become the first disease-modifying XLRP therapy.
Read more →Science and Discovery
A Sleep Drug Just Aced an ADHD Test
Alkermes showed that its orexin 2 receptor agonist, a class designed for wakefulness, can meaningfully improve ADHD symptoms. In a 50-patient Phase 1b trial, the higher dose produced a median 19-point reduction in ADHD scores, with zero serious adverse events. If Phase 2 confirms it in 2027, this could be the first genuinely new ADHD mechanism in decades.
Read more →A Thyroid Hormone Drug Just Crushed Bipolar Depression Scores
Autobahn Therapeutics' elunetirom posted a 16.8-point drop in depression scores with a p-value below 0.001 in Phase 2 for bipolar depression. Half of patients hit remission at six weeks. The drug doesn't touch serotonin or dopamine; it targets thyroid hormone receptors in the brain to fix cellular energy production. A completely new category if Phase 3 holds up.
Read more →Deals and Strategy
Telix Just Wrote a $1.6B Check to Pick a Fight With Novartis
Australian radiopharma company Telix is acquiring ITM Isotope Technologies Munich for up to $2.35 billion, the largest mid-cap radiopharmaceutical deal announced in 2026. The move gives Telix control of lutetium-177 isotope manufacturing and a Phase 3 competitor to Novartis's Lutathera. For the first time, one company outside Novartis could challenge both pillars of its radioligand empire.
Read more →Novo Nordisk Buys an Obesity Playbook That Has Nothing to Do With GLP-1
Novo acquired three non-incretin obesity programs from gut-brain biotech Kallyope, including a potential first-in-class peptide that suppresses appetite without the nausea plaguing current drugs. The deal converts a years-long research collaboration into outright ownership, signaling that even the GLP-1 king thinks one mechanism won't be enough as Lilly, Amgen, and others close in.
Read more →BMS Deploys Pharma's Most Powerful AI Supercomputer
Bristol Myers Squibb expanded its Nvidia partnership to deploy what it calls the most powerful single-owned AI computing system in life sciences, going live Q1 2027. The goal: predict which drug candidates will work before anyone synthesizes a molecule. Industry AI spending is projected to hit $25 billion by 2030, but the real test remains whether all that compute produces better drugs.
Read more →